Non-small cell lung cancer (NSCLC) represents almost 85% of total diagnosed lung cancer.
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide, with nearly 1.4 million deaths each year (1) . Non-small cell lung cancers (NSCLC) constitute almost 85% of total diagnosed cases and are caused mainly due the exposure to the environmental carcinogens. The early stages of lung tumorigenesis involve reversible promoter methylation and histone modification changes (2) . Bioactive natural compounds can be defined as the natural compounds which can exhibit a biological activity on the living cells. These compounds possess the capability to reverse the epigenetic alterations. Bioactive natural compounds have been shown to restore the expressions of oncogenes and tumor suppressor genes (TSGs) altered during the course of carcinogenesis (2, 3) . Therefore, the uses of bioactive natural compounds have been a major focus of interest as therapeutic options against various classes of diseases including cancer.
The use of DNA methyltransferase (DNMT) inhibitors alone or in combination with histone deacetylase (HDAC) inhibitors has shown promising results against various cancers through active chromatin modifications (4) (5) (6) (7) . However, use of synthetic inhibitors invites several limitations including cost, dose-regime and adverse side-effects. Therefore, studies have aimed to use natural DNMT inhibitors alone or in combinations with natural HDAC inhibitors for the prevention and treatment of cancers (7, 8) . We have previously shown that Cucurbitacin B (CuB) is a natural triterpenoid isolated from Cucurbitaceae plants and it has been shown to have anti-plasmodial, immuno-modulatory, free-radical scavenging, hepatoprotective, cardiovascular, anti-inflammatory, anti-helminthic and anti-fertility activities (9) (10) (11) (12) . Recently, there has been growing interest in CuB-mediated anti-cancer activities, mainly mediated through induction of G 2 /M phase cell cycle arrest, inhibition of JAK/STAT pathway and induction of apoptosis (13) (14) (15) (16) (17) (18) (19) . However, these studies have not elucidated the core epigenetic mechanisms behind the anti-cancer activities of CuB. Our results demonstrate for the first time that CuB, a single bioactive natural compound, exhibits both HDACs and DNMTs inhibitory activities at sub-IC 50 concentrations in nanomolar range in NSCLC cells. This altered expressions of epigenetic enzymes further led to changes in the expression patterns of TSGs, TPG and oncogenes in the mice lung tissues.
Materials and Methods

Isolation of cucurbitacin B
CuB was isolated from the fruits of L. graveolense Roxb. as described in the Supplementary   Table S1 . The structure of CuB was elucidated on the basis of spectroscopic analysis described in the Supplementary Table S1, which was in good agreement with that of previously reported (20 
Cell culture and cell proliferation assay
The human NSCLC cells were purchased from ATCC (Manassas, VA) and no authentication was done by the authors except performing a mycoplasma test using the LookOut Mycoplasma PCR-detection kit (Sigma-Aldrich). Cells were cultured and maintained in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin solution in a humidified atmosphere at 37 0 C with 5% CO 2 . CuB was dissolved in ethanol and stored at a stock concentration of 10 mM at 4°C. The maximum final concentration of ethanol in the complete culture medium was less than 0.1% (v/v). Cell proliferation was assayed by standard MTT assay as described previously (6) . and β-actin (Cell Signalling). The membranes were then incubated with respective secondary antibody. Immunoreactive bands were visualized using the enhanced chemiluminescence detection system.
Cell cycle distribution and apoptosis analysis
HDACs and DNMTs activity assays
The HDACs and DNMTs activities were analyzed using the colorimetric assay kits (Active Motif, Carlsbad, CA) as described previously (21, 22) .
Southwestern dot-blot analysis
The effect of CuB treatment on the degree of genomic methylation was determined using dotblot analysis, as described previously (6) . Briefly, 1 µg of genomic DNA was transferred onto a nitrocellulose membrane and fixed by baking the membrane for 1 h at 80°C. After blocking the nonspecific binding sites, the membrane was incubated with the anti-5-methyl cytosine (5-mC) antibody (MABE146; Millipore) for 2 h. Further, the membrane was incubated with HRP-conjugated secondary antibody and bands were visualized using chemiluminescence detection system.
Methylation-specific PCR (MSP) assay
The DNA methylation statuses of the p21 CIP1/WAF1 and hTERT promoters were assessed by MSP using the EpiTect Bisulfite modification kit (Qiagen, Valencia, CA) following the manufacturer's protocol. After 48 h of CuB treatment, 2 µg of genomic DNA was bisulfite 
Chromatin Immunoprecipitation (ChIP) assay
ChIP assays were performed using the EZ-ChIP kit according to the manufacturer's protocol (Millipore) as described previously (21, 22 
Results
CuB inhibits cellular proliferation and induces cellular apoptosis
To determine the effective dose of CuB on human NSCLC cells, we performed cellular proliferation, cell cycle arrest and apoptosis analyses. We observed a dose-and time- 
CuB alters the expression of key tumor-related genes
As shown in Fig. 1D , CuB at concentrations of 60 nM or higher, significantly increased the mRNA and proteins expression of key cell cycle regulatory TSGs such as p16 INK4A and p21 CIP1/WAF1 in H1299 cells. However, we found slightly decreased mRNA expressions of these TSGs at 600 nM as compared to 60 nM CuB concentrations, which might be due to the mRNA instability as well as higher rate of protein turnover observed in case of cell cycle regulators (26, 27) . Overall, these mRNA and protein expressions are consistently up in Fig.1F , CuB treatment significantly reduced the expression of hTERT, the catalytic subunit of telomerase, starting with a dose of 6 nM onwards at 48 h. Therefore, these results suggest that the anti-proliferative and pro-apoptotic effects of CuB are, at least in part, associated with the altered expressions of key tumor-related genes in NSCLC cells.
CuB altered the expression and activity of epigenetic modulatory enzymes
Genetic alterations are accompanied by epigenetic modulations during carcinogenesis (2, 6).
Hence, we analyzed the expressions of both types of DNMTs, maintenance methyltransferase DNMT1, and de novo methyltransferases, DNMT3a and DNMT3b. As shown in Fig. 2A , CuB treatment significantly inhibited the expressions of DNMT1 and DNMT3b starting from CuB concentrations of 600 nM or higher in H1299 cells. Interestingly, the protein expressions of all the three DNMTs were drastically reduced starting from IC 50 concentration of CuB in H1299 cells (Fig. 2B) . Further, we have also observed a significant inhibition of DNMTs activity starting with the CuB concentrations of 200 nM in another NSCLC A549 cell line (Supplementary Fig. S1D ). In addition to DNMTs, HDACs, especially HDAC1, HDAC5 and HDAC6 were found to be considerably downregulated by CuB starting with 60 nM concentrations in H1299 cells. NAD + -dependent class III HDACs, SIRT3 and SIRT6
were also found to be downregulated at 60 nM or higher concentrations of CuB. We further analyzed the protein expressions of different histone acetyltransferases (HATs) such as CBP, GCN5L2, PCAF and p300 after CuB treatment in H1299 cells for 48 h. We found that CBPand PCAF-expressions were marginally upregulated at sub-IC 50 and IC 50 concentrations of CuB (Fig. 2C) . Further, CuB not only inhibited the expressions, but also dose-dependently inhibited the activity of HDACs in NSCLC cells ( Fig. 2D; Supplementary Fig. S1D ). Fig. S2A) . Further, as shown in Supplementary Fig. S2B . As shown in Fig. 3B -C, we selected three different histone acetylation marks such as acetyl histone 3 (AcH3), acetyl histone 4 (AcH4) and acetylation at lysine 9 of histone 3 (AcH3K9) as active chromatin marks. We found significantly higher enrichment of AcH3 at both proximal and distal promoters of 
In case of the p21 CIP1/WAF1 promoter, we designed two distinct sets of primers for two functionally important regions of the distal promoter as shown in Fig. 4A . The primer pair amplifying ChIP 1 flanks a sp1-binding site on the p21 CIP1/WAF1 promoter. Enrichment of AcH3 was found to be significantly increased at CuB concentrations of 6 and 60 nM (P<0.05), while the enrichment of AcH4 and AcH3K9 showed no significant alteration at both the promoter sites (Fig. 4B-C upregulation with CuB treatment in p53 (-) H1299 cells.
Similarly, we designed five sets of primers for the hTERT promoter spanning the regions from distal promoter to the first exonic region (Fig. 5A) . As shown in Fig. 5B-C (Fig. 5B-C) . Collectively, these results suggest that the CuB-mediated chromatin modifications are, at least in part, responsible for the altered expressions of p16 INK4A , p21 CIP1/WAF1 and hTERT in H1299 cells.
CuB inhibits NNK-induced lung tumorigenesis
Next, we sought to determine the effect of CuB on NNK-induced lung tumorigenesis. The schematic experimental design is given in Fig. 6A . We found no significant difference in the average body weights of mice in the individual groups ( Supplementary Fig. S3A ).
Histopathological examination revealed that the lungs of NNK-induced mice showed a highest grade of bronchiolar and alveolar hyperplasia, adeno-carcinoma and micro-adenomas compared to the lungs of vehicle-treated control mice ( Fig. 6B; Supplementary Fig. S3B and Table S4 ). Tumor angiogenesis, which is marked by the formation of new and irregular blood vessels, was also prevalent in the NNK-induced lungs, which decreased dose-dependently in CuB-treated groups ( Fig. 6B; Supplementary Fig. S3B and Table S4 ). As shown in Fig. 6C , NNK-administrated mice had significantly higher incidence of lung cancer (100%) and tumor multiplicity (17.75±7.4 lung tumors per mouse) compared with vehicle-administered control mice. Interestingly, treatment with CuB resulted in a significantly reduced tumor incidence and tumor multiplicity compared with vehicle-treated NNK-induced lung tissues (Fig. 6C) .
Further, as shown in Fig. 6D , the presence of PCNA was highest in the NNK-administrated (Fig. 6D) .
Cancer Research. Overall, CuB-inhibited hyper-proliferation and enhanced cell death in NNK-induced hyper proliferative lung cancer in A/J mice.
CuB alter the expressions of epigenetic enzymes and tumor-related genes in NNKinduced lung tissues
To further validate our in vitro results, we analyzed the expressions of epigenetic modulatory enzymes in the CuB-treated and untreated NNK-induced mice lungs. As shown in the (Fig. 6F) . In accordance, we have also observed a considerable downregulation of the expressions of oncogenes c-MYC and RAS in CuB-treated mice lungs compared to NNK-induced lung tissue (Fig. 6F) . In addition to alterations in DNA methylation, chromatin modifications also play major role in gene regulation in cancers. In general, HDACs are frequently over expressed in many cancers and inhibition of HDACs induces re-expression of epigenetically silenced genes (7, 8, 28) . Our results suggest that CuB-mediated HDACs inhibition altered the accessibility of various transcriptional factors to the promoters of the TSGs and TPG in H1299 cells. Further, we also observed that CuB at 6 nM concentration induced both class I and class II HDACs, which seems to be the cellular survival strategy to combat with the autophagic effects of CuB The changes in the expression and activities of epigenetic modulatory enzymes lead to alterations in histone modifications. In general, the acetylation at H3K9 results into gene activation, whereas methylation at H3K9 (H3K9me3) results into gene repression (2, 28, 36) .
DISCUSSION
It is a well established fact that the site and degree of histone methylation defines its role in gene regulation (37) . The sites with higher enrichment of histone methylation marks, H3K9me3 and H3K27me3, represent transcriptionally inactive regions of chromatin. We found significantly lowered enrichment of these histone methylation marks at the promoters This finding becomes even more significant due to the strong anti-cancer activity exhibited by a low concentration of CuB against NSCLC. In conclusion, our results suggest that CuB could be developed as a very potent lung anti-cancer molecule and it could also be used in designing novel epigenetic therapeutic strategy against NSCLC in humans. 
